We are a global healthcare company, founded in 1923 and headquartered just outside Copenhagen, Denmark.
Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity, and rare blood and rare endocrine diseases.
We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure the diseases we treat.
We employ more than 44,000 people in 80 offices around the world, and market our products in 170 countries.
production sites in nine countries (Algeria, Brazil, China, Denmark, France, Japan, Russia, UK and US).
research and development centres in five countries (China, Denmark, India, UK and US).
of our employees are located in Denmark.
number of countries we provide access to our products.
We will not allow the success of our company to be defined by the steady increase in the number of people living with serious chronic diseases, like type 2 diabetes and obesity.
We take no pleasure in the suffering and hardships faced by people living with a chronic disease. In some countries, the financial burden of providing or getting access to medical care puts people at risk of serious health complications.
We are committed to helping societies defeat diabetes, and our strategy is clear – accelerate prevention of type 2 diabetes and obesity, and provide access to affordable care for vulnerable patients in every country.
Our success will be defined by the solutions we bring and the health and well-being of the people and communities benefiting from them.
We are the first pharmaceutical company to use 100% renewable power in all our global production facilities. We are proud but also motivated to go even further.
With our Circular for Zero strategy, we are starting a journey to achieve zero environmental impact in all our business activities.
We will collaborate proactively with suppliers to reduce the environmental impact across our supply chain, cut CO2 emissions from all our operations and transportation, and solve the end-of-life product waste challenge to eliminate waste.
Marie Darting and Pernille Thomasen, Novo Nordisk Denmark
In 1930, Novo delivered insulin to about 40 countries.